World journal of urology · 2025
Impact on oncological outcomes of detrusor muscle absence in pTaHG urothelial carcinoma of the bladder? The end of the "jump" of the lamina propria layer myth.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tissot Gabrielle, Gabriel Pierre-Etienne, Dubuet Ulysse, Régnier Sophie, Ouzaid Idir, Moschini Marco, Soria Francesco, D'Andrea David, Shariat Shahrokh F, Budowski Alexandra, Poyet Cédric, Roumiguie Mathieu, Maestro Mario Alvarez, Briganti Alberto, Krajewski Wojciech, Hendricksen Kees, Veerman Hans, Afferi Luca, Mattei Agostino, Di Bona Carlo, Zamboni Stefania, Simeone Claudio, Thenault Ronan, Verhoest Gregory, Hermieu Jean-François, Xylinas Evanguelos
Аннотация
PURPOSE: To evaluate the impact of detrusor muscle (DM) absence on oncological outcomes in patients with pTaHG within a large, multicenter cohort.
METHODS: This is a retrospective multicenter study based on a national database including 12 international expert centers. All patients who underwent transurethral resection of bladder tumor (TURBT) for a new diagnosis of pTaHG bladder cancer between January 2010 and December 2018 were included and divided into two groups according to the presence or absence of DM. Kaplan-Meier curves were used to illustrate survival outcomes, while Cox regression analyses were conducted to identify independent predictors of survival.
RESULTS: Overall, 418 patients had either pTaHG with DM (n = 365;87.3%) or without DM (n = 53;12.7%). After a median follow-up of 30 months, IQR [15;55], the 5-year RFS (40% vs. 50%; p = 0.2) and the 5-year PFS (75% vs. 86%; p = 0.2) were similar between both groups. Cox-regression analysis confirmed that absence of DM was not significantly associated with RFS (HR = 0.68; 95%CI= [0.41-1.15]; p = 0.15) and PFS (HR = 0.68; 95%CI= [0.27-1.69]; p = 0.40). Among 53 patients without DM, 29 (54.7%) underwent a second-look TURBT, with no impact on 5-year RFS (p = 0.1) and 5-year PFS (p = 0.07). Additionally, Cox-regression analysis confirmed that the absence of second-look was not associated with RFS (HR = 0.28; 95%CI= [0.09-0.93]; p = 0.04) and PFS (HR = 0.05; 95%CI= [0.00-0.89]; p = 0.04).
CONCLUSION: Absence of DM on pathological specimen of pTaHG tumors had no impact on disease recurrence or progression occurrence, calling into question the need for routine second-look procedures for these patients.
METHODS: This is a retrospective multicenter study based on a national database including 12 international expert centers. All patients who underwent transurethral resection of bladder tumor (TURBT) for a new diagnosis of pTaHG bladder cancer between January 2010 and December 2018 were included and divided into two groups according to the presence or absence of DM. Kaplan-Meier curves were used to illustrate survival outcomes, while Cox regression analyses were conducted to identify independent predictors of survival.
RESULTS: Overall, 418 patients had either pTaHG with DM (n = 365;87.3%) or without DM (n = 53;12.7%). After a median follow-up of 30 months, IQR [15;55], the 5-year RFS (40% vs. 50%; p = 0.2) and the 5-year PFS (75% vs. 86%; p = 0.2) were similar between both groups. Cox-regression analysis confirmed that absence of DM was not significantly associated with RFS (HR = 0.68; 95%CI= [0.41-1.15]; p = 0.15) and PFS (HR = 0.68; 95%CI= [0.27-1.69]; p = 0.40). Among 53 patients without DM, 29 (54.7%) underwent a second-look TURBT, with no impact on 5-year RFS (p = 0.1) and 5-year PFS (p = 0.07). Additionally, Cox-regression analysis confirmed that the absence of second-look was not associated with RFS (HR = 0.28; 95%CI= [0.09-0.93]; p = 0.04) and PFS (HR = 0.05; 95%CI= [0.00-0.89]; p = 0.04).
CONCLUSION: Absence of DM on pathological specimen of pTaHG tumors had no impact on disease recurrence or progression occurrence, calling into question the need for routine second-look procedures for these patients.